Safety Study of Rufinamide Given as an add-on Therapy to Treat Patients With Seizures

Refractory Partial Seizures Clinical Trial

Official title:
A Double-Blind, Placebo-Controlled, Parallel-Group Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

Status Withdrawn

Clinical Trial Summary

This study will evaluate the efficacy and safety of Rufinamide in reducing seizure frequency in subjects with partial seizures not fully controlled despite treatment with 1 to 3 concomitant antiepileptic drugs.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04558580
Study type	Interventional
Source	University of South Alabama
Contact
Status	Withdrawn
Phase	Phase 3
Start date	April 2006
Completion date	December 2008

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00699582` - To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures	Phase 3
Completed	`NCT00903786` - A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)	Phase 2
Completed	`NCT00700310` - Evaluating Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures	Phase 3
Completed	`NCT00699972` - Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures	Phase 3
Completed	`NCT00849212` - An add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-epileptic Drugs (AEDs)	Phase 2